Richter’s Biosimilar Costs ‘Took Up A Lot Of Resources Last Year’
Growth For Teriparatide Biosimilar Terrosa Expected To Slow In 2022
Hungary’s Gedeon Richter is continuing to divert the greatest proportion of its R&D cash to biosimilars. Management updated on its pipeline and broader group prospects amid Russia’s military invasion of Ukraine.
